Secondary infections found in hospital environments are becoming an increasingly significant concern for patients, hospital administrators, and staff. Patient care can be negatively affected when a secondary infection caused by a variety of microorganisms commonly found in healthcare environments leads to health issues for a patient. With insurance companies no longer covering the expense for secondary infections, the cost to hospitals for the infections can lead to a negative return on their bottom line.
Evonik has introduced three new products that can resist the growth of bacteria which can be molded into medical devices that have 510(k) applications and have shown efficacy as tested per the JIS Z 2801 Protocol.
Larry Gabriel, Business Development Manager, Evonik Cyro LLC
Larry is a 30-year veteran of Evonik,
having worked in the sales and product development areas of the
medical industry since the mid-1980s. Focusing his efforts in the
medical device industry throughout his career, Larry works directly
with Evonik's medical customer base in identifying the specific
product requirements related to the development of Evonik's new line
of antimicrobial products.
Dimo Dimov, Product Development Project Manager, Molding Compounds, Evonik Cyro LLC
Dimo has a BS degree in Chemical
Engineering and PhD degree in Polymer Chemistry. Research interests
are in physical organic chemistry, vinyl polymerization, and
advanced acrylics for medical, optical and specialty